ELAN
Elanco Animal Health Incorporated
NYSE · Healthcare · Drug Manufacturers - Specialty & Generic · US
$24.38
−0.14%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 5.0B | 4.7B | 4.4B | 4.4B | 4.4B |
| Cost of Revenue | 2.4B | 2.7B | 2.5B | 2.5B | 2.4B |
| Gross Profit | 2.6B | 2.0B | 1.9B | 1.9B | 2.0B |
| Operating Expenses | |||||
| R&D Expense | 371.0M | 368.0M | 344.0M | 327.0M | 321.0M |
| SG&A Expense | 1.5B | 1.4B | 1.3B | 1.3B | 1.3B |
| General & Admin Expense | 351.0M | — | 1.1B | — | — |
| Selling & Marketing Expense | 449.0M | — | 236.0M | — | — |
| Other Expenses | 288.0M | — | — | — | — |
| Total Operating Expenses | 2.2B | 1.8B | 1.7B | 1.6B | 1.6B |
| Cost and Expenses | 4.6B | 4.5B | 4.2B | 4.1B | 4.0B |
| Operating Income (EBIT) | 462.0M | 252.0M | 251.0M | 326.0M | 384.0M |
| Non-Operating | |||||
| Interest Income | 11.0M | 45.0M | — | — | — |
| Interest Expense | 259.0M | 220.0M | 339.0M | 277.0M | 256.0M |
| Net Interest Income | (248.0M) | (175.0M) | (339.0M) | (277.0M) | (256.0M) |
| Other Non-Op Income/Expense | (628.0M) | (476.0M) | 237.0M | (1.5B) | (456.0M) |
| Non-Operating Income (excl Interest) | 381.0M | 256.0M | (576.0M) | 1.2B | 200.0M |
| EBT (Pre-Tax Income) | (166.0M) | (224.0M) | 488.0M | (1.2B) | (72.0M) |
| Income Tax Expense | 33.0M | 8.0M | 150.0M | 36.0M | 6.0M |
| Bottom Line | |||||
| Net Income | (199.0M) | (232.0M) | 338.0M | (1.2B) | (78.0M) |
| Earnings from Cont. Ops | (199.0M) | (232.0M) | 338.0M | (1.2B) | (78.0M) |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | (199.0M) | (232.0M) | 338.0M | (1.2B) | (78.0M) |
| Per Share | |||||
| Basic EPS | ($0.41) | ($0.47) | $0.68 | ($2.50) | ($0.15) |
| Diluted EPS | ($0.40) | ($0.47) | $0.68 | ($2.50) | ($0.15) |
| Revenue Per Share | $10.05 | $9.50 | $8.99 | $8.97 | $9.03 |
| Shares | |||||
| Basic Shares Outstanding | 499.5M | 496.4M | 494.0M | 492.3M | 488.3M |
| Diluted Shares Outstanding | 505.9M | 496.4M | 497.3M | 492.3M | 488.3M |
| Profitability Metrics | |||||
| EBITDA | 774.0M | 676.0M | 1.5B | (224.0M) | 866.0M |
| D&A | 693.0M | 680.0M | 662.0M | 694.0M | 682.0M |
| EBIT | 81.0M | (4.0M) | 827.0M | (918.0M) | 184.0M |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026